Dr. Aldape will work together with the biotech business to assist the development of their cancer action predictor platform
Tel Aviv, Israel– WEBWIRE– Wednesday, October 2, 2024
Pangea Biomed, the start-up behind the worlds most sophisticated cancer reaction predictor, ENLIGHT, revealed that Dr. Kenneth D. Aldape, M.D., has actually signed up with the business clinical board of advisers.
Dr. Aldape, an internationally acknowledged molecular neuropathologist, is Chief of the National Cancer Institute (NCI) Lab of Pathology. He is a leading figure in his field, respected for his prominent work utilizing methylation patterns (chemical adjustments) for the sub-classification of brain growths, which is thought about the most precise tool for brain growth medical diagnosis.
Weve been working together with Dr. Aldape for many years, around NCI trials to evaluate our ENLIGHT platform, described Pangea CEO Tuvik Beker. Now, with him on our clinical board of advisers, were delighted for his tactical competence and input in forming the instructions of our research study and advancement efforts.
Dr. Aldape has actually formerly held professors positions at the University of California, San Francisco, at MD Anderson Cancer Center, where he functioned as department chair of pathology and at Princess Margaret Cancer Centre, where he acted as a senior researcher. He is acknowledged as a leader in using molecular innovations to advance accuracy growth diagnostics.
As a consultant to Pangea, I eagerly anticipate getting an even much better understanding of the abilities of enhanced cancer diagnostics and treatments for clients, stated Dr. Aldape. As we work carefully together, we want to create brand-new innovations that add to client well-being.
Dr. Aldapes function as a Pangea clinical board of advisers member is acknowledged as part of his main tasks by The National Institutes of Health (NIH), guaranteeing it lines up with his duties within the company and in external cooperations.
Dr. Aldapes visit to Pangeas clinical board of advisers carefully follows that of Dr. Lillian Siu, a senior medical oncologist at Princess Margaret Cancer Centre, teacher of medication at the University of Toronto and the existing president of the American Association for Cancer Research (AACR).
In addition to Dr. Aldape and Dr. Siu, the clinical board of advisers consists of:
-
Raanan Berger, MD, Ph.D., Director of the Cancer Center at Sheba Medical Center
-
J. Silvio Gutkind, Ph.D., Professor and Chair of the Department of Pharmacology at UCSD School of Medicine and Associate Director for Basic Science at Moores Cancer Center
-
Dan A. Landau, MD, Ph.D., Assistant Professor at Weill Cornell Medical College and Core Member at the New York Genome Center
-
Gideon Rechavi, MD, Ph.D., head of Sheba Cancer Research Center and head of the Wohl Institute for Translational Medicine
-
Zeev Ronai, Ph.D., Director of the NCI-Designated Cancer Center at Sanford Burnham Prebys Discovery Institute
-
Eytan Ruppin, MD, Ph.D., Chief of the Cancer Data Science Lab at the National Cancer Institute
To read more about Pangea and ENLIGHT,